N-(1-naphthylsulfonyl)-(L)-tryptophanol | 161708-74-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(1-naphthylsulfonyl)-(L)-tryptophanol
• 英文别名: N-[(2S)-1-hydroxy-3-(1H-indol-3-yl)propan-2-yl]naphthalene-1-sulfonamide
• CAS: 161708-74-3
• 化学式: C₂₁H₂₀N₂O₃S
• 分子量: 380.467
• InChiKey: UMSUNWYRWZVWDL-KRWDZBQOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  90.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  benzyl (S)-(1-hydroxy-3-(1H-indol-3-yl)propan-2-yl)carbamate 、 1,4-二氧六环 、 1-萘磺酰氯 、 三乙胺 在 palladium-carbon palladium-carbon 、 乙醚 、 柠檬酸 、 碳酸氢钠 、 magnesium sulfate 、 ethyl acetate n-hexane 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 水 为溶剂， 反应 16.0h， 以to yield a powder of N-(1-naphthylsulfonyl)-(L)-tryptophanol (0.8 g, 68%)的产率得到N-(1-naphthylsulfonyl)-(L)-tryptophanol
  参考文献：
  名称：

  Alcohol or aldehyde derivatives and their use

  摘要：

  本发明提供一种含有式子的化合物的半胱天冬酶L抑制剂：##STR1##其中R.sup.1是氢原子或取代基的芳基烷基，杂环烷基或较低的烷基；R.sup.2和R.sup.3独立地是氢原子或可取代的碳氢基；R.sup.4是可取代的烷酰基，磺酰基，羰氧基，氨基甲酰基或硫代氨基甲酰基；X是公式：--CHO或--CH.sub.2 OB（其中B是氢原子或羟基的保护基）；m和n独立地是0或1的整数；条件是当R.sup.1是未取代的较低烷基、芳基烷基或甲基硫乙基时，R.sup.4是取代的烷酰基，取代的含有9个以上碳原子的芳基磺酰基或较低的烷基，或可取代的氨基甲酰基或硫代氨基甲酰基，且R.sup.2和R.sup.3独立地是较低的烷基或芳基烷基，X是--CHO，m是1，n是0或1，或其盐。化合物（I）可用作预防/治疗骨质疏松症的药物。

  公开号：

  US05716980A1

文献信息

• Derivatives of L-tryptophanal and their use as medicinals
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05498728A1

  公开（公告）日：1996-03-12

  The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof. Compound (I) is useful as a prophylactic/therapeutic agent for osteoporosis.

  本发明提供了一种含有式为：##STR1##的化合物的半胱氨酸蛋白酶L抑制剂，其中R.sup.1为氢原子或取代的芳基烷基，杂环基烷基或低级烷基；R.sup.2和R.sup.3独立地为氢原子或可取代的碳氢残基；R.sup.4为可取代的烷酰基，磺酰基，羰氧基，氨基甲酰基或硫脲甲酰基；X为公式：--CHO或--CH.sub.2 OB（其中B为氢原子或羟基保护基）；m和n独立地为0或1的整数；前提是当R.sup.1为未取代的低级烷基，芳基烷基或甲基硫乙基时，R.sup.4为取代的烷酰基，芳基取代的磺酰基具有9个以上的碳原子或低级烷基，或可取代的氨基甲酰基或硫脲甲酰基，R.sup.2和R.sup.3独立地为低级烷基或芳基烷基，X为--CHO，m为1，n为0或1，或其盐。化合物（I）可用作骨质疏松症的预防/治疗药物。
• Method for treating osteoporosis
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05955491A1

  公开（公告）日：1999-09-21

  The present invention provides a cathepsin L inhibitor containing a compound of the formula: ##STR1## wherein R.sup.1 is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R.sup.2 and R.sup.3 independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R.sup.4 is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: --CHO or --CH.sub.2 OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R.sup.4 is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R.sup.1 is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R.sup.2 and R.sup.3 independently are a lower alkyl or arylalkyl, X is --CHO, m is 1 and n is 0 or 1, or a salt thereof.

  本发明提供了一种含有公式化合物的cathepsin L抑制剂：##STR1## 其中R.sup.1是氢原子或可被取代的芳基烷基，杂环烷基或较低的烷基基团; R.sup.2和R.sup.3独立地是氢原子或可被取代的碳氢残基; R.sup.4是可被取代的烷酰基，磺酰基，羰氧基，氨基甲酰基或硫氨基甲酰基基团; X是公式：--CHO或--CH.sub.2 OB（其中B是氢原子或羟基的保护基团）; m和n独立地是0或1的整数; 前提是当R.sup.1是未取代的较低的烷基，芳基烷基或甲基硫乙基时，R.sup.4是被芳基取代的烷酰基，被具有9个以上碳原子的芳基或较低的烷基取代的磺酰基，或可被取代的氨基甲酰基或硫氨基甲酰基时，R.sup.2和R.sup.3独立地是较低的烷基或芳基烷基，X是--CHO，m为1且n为0或1，或其盐。
• Alcohol or aldehyde derivatives as cathepsin L inhibitor and bone resorption inhibitor
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0611756A2

  公开（公告）日：1994-08-24

  The present invention provides a cathepsin L inhibitor containing a compound of the formula: wherein R¹ is a hydrogen atom or an arylalkyl, heterocyclic-alkyl or lower alkyl group which may be substituted; R² and R³ independently are a hydrogen atom or a hydrocarbon residue which may be substituted; R⁴ is an alkanoyl, sulfonyl, carbonyloxy, carbamoyl or thiocarbamoyl group which may be substituted; X is formula: -CHO or -CH₂OB (wherein B is a hydrogen atom or a protecting group of hydroxyl group); m and n independently are an integer of 0 or 1; provided that R⁴ is an alkanoyl group substituted by aryl, a sulfonyl group substituted by aryl having more than 9 carbon atoms or by lower alkyl, or a carbamoyl or thiocarbamoyl group which may be substituted when R¹ is an unsubstituted lower alkyl, arylalkyl on methylthioethyl group, R² and R³ independently are a lower alkyl or arylalkyl, X is -CHO, m is 1 and n is 0 or 1, or a salt thereof. Compound (I) is useful as a prophylactic/therapeutic agent for osteoporosis.

  本发明提供了一种含有式化合物的凝血酶 L 抑制剂： 其中，R¹为氢原子或可被取代的芳烷基、杂环烷基或低级烷基；R²和R³各自为氢原子或可被取代的烃残基；R⁴为可被取代的烷酰基、磺酰基、羰氧基、氨基甲酰基或硫代氨基甲酰基；X为式：-CHO或-CH₂OB（其中 B 为氢原子或羟基保护基团）；m 和 n 分别为 0 或 1 的整数；条件是 R⁴ 是被芳基取代的烷酰基、被具有 9 个以上碳原子的芳基或低级烷基取代的磺酰基、或当 R¹ 是未取代的低级烷基、芳烷基或甲硫基时可能被取代的氨基甲酰基或硫代氨基甲酰基，R² 和 R³ 独立地是低级烷基或芳烷基，X 是 -CHO，m 是 1，n 是 0 或 1，或其盐。 化合物 (I) 可用作骨质疏松症的预防/治疗剂。
• US5498728A
  申请人：——

  公开号：US5498728A

  公开（公告）日：1996-03-12
• US5639781A
  申请人：——

  公开号：US5639781A

  公开（公告）日：1997-06-17